BioNTech SE (BNTX) Total Non-Current Liabilities (2018 - 2025)
BioNTech SE (BNTX) posted Total Non-Current Liabilities of $724.2 million for Q4 2025, down 3.41% sequentially from $749.7 million in Q3 2025, and up 13.82% YoY from $636.2 million in Q4 2024.
BioNTech SE (BNTX) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
BioNTech SE has reported Total Non-Current Liabilities for 8 years, with the latest figure at $724.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 13.82% year-over-year to $724.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $724.2 million (up 13.82% YoY) and the FY2025 annual result came in at $702.9 million, up 10.47% from the prior year.
- Total Non-Current Liabilities retreated to $724.2 million in Q4 2025 per BNTX's latest filing, from $749.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.5 billion in Q2 2025 and troughed at $278.4 million in Q4 2022.
- A 5-year average of $639.9 million and a median of $620.8 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities jumped 237.3% in 2021, then tumbled 53.47% in 2022.
- Over 5 years, Total Non-Current Liabilities stood at $521.1 million in 2021, then slumped by 46.57% to $278.4 million in 2022, then jumped by 166.6% to $742.3 million in 2023, then declined by 14.29% to $636.2 million in 2024, then rose by 13.82% to $724.2 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $724.2 million, $749.7 million, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 724.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 724.15 Mn |
| Sep 30, 2025 | 749.72 Mn |
| Jun 30, 2025 | 1.45 Bn |
| Mar 31, 2025 | 758.72 Mn |
| Dec 31, 2024 | 636.24 Mn |
| Sep 30, 2024 | 839.26 Mn |
| Jun 30, 2024 | 796.57 Mn |
| Mar 31, 2024 | 741.55 Mn |
| Dec 31, 2023 | 742.29 Mn |
| Sep 30, 2023 | 580.44 Mn |
| Jun 30, 2023 | 544.57 Mn |
| Mar 31, 2023 | 282.07 Mn |
| Dec 31, 2022 | 278.43 Mn |
| Sep 30, 2022 | 339.39 Mn |
| Jun 30, 2022 | 427.89 Mn |
| Mar 31, 2022 | 599.78 Mn |
| Dec 31, 2021 | 521.08 Mn |
| Sep 30, 2021 | 729.39 Mn |
| Jun 30, 2021 | 605.39 Mn |
| Mar 31, 2021 | 451.13 Mn |